IFNA1 and COVID-19: However, caution might be warranted for such therapy during later stage COVID-19 as type I and III IFN signaling are shown herein to drive inflammatory responses during SARS-CoV-2 infection, and are also known to have pro-inflammatory activities in other settings [107].